News from biodelivery sciences international, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 12, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Announces BEMA Buprenorphine NDA Submission on Track following Pre-NDA Meeting with FDA

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that along with its commercial partner, Endo Pharmaceuticals, engaged in a...

Aug 07, 2014, 16:45 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2014 Financials

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended...

Aug 06, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that it has completed a pre-specified interim analysis of the ongoing...

Jul 22, 2014, 08:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors

BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that its Board of Directors has appointed Charles J. (Chuck) Bramlage and...

Jun 26, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Announces Completion of Patient Enrollment in its Initial Phase 3 Trial of Clonidine Topical Gel for Painful Diabetic Neuropathy

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has completed enrollment of all patients required for its initial...

Jun 11, 2014, 11:34 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Featured on Bloomberg TV, TheStreet.com and Business News Network

 Dr. Mark A. Sirgo, President and Chief Executive Officer of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) was interviewed on...

Jun 10, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences to Present at the William Blair and Wells Fargo Healthcare Conferences

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will...

Jun 09, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Receives FDA Approval for BUNAVAIL™ (buprenorphine and naloxone) Buccal Film for the Maintenance Treatment of Opioid Dependence

 BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) received approval of the New Drug Application (NDA) for BUNAVAIL™...

Jun 06, 2014, 17:19 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Receives FDA Approval for BUNAVAIL™ (buprenorphine and naloxone) Buccal Film for the Maintenance Treatment of Opioid Dependence

 BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) received approval of the New Drug Application (NDA) for BUNAVAIL™...

May 08, 2014, 18:00 ET

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2014 Financials

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended March...

May 08, 2014, 07:00 ET

BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will...

May 06, 2014, 07:00 ET

BioDelivery Sciences Announces Randomization of Over 50% of Subjects in its Initial Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has randomized more than half of the planned number of patients required...

Apr 07, 2014, 09:40 ET

BioDelivery Sciences Announces Four BUNAVAIL Abstracts to be Presented at the 2014 American Society of Addiction Medicine Annual Conference

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that data from clinical studies of BUNAVAIL  will be presented...

Apr 03, 2014, 07:00 ET

BioDelivery Sciences Announces Enrollment of the First Patient in a Phase 3 Clinical Study of Clonidine Topical Gel for Painful Diabetic Neuropathy

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3...

Mar 27, 2014, 07:00 ET

BioDelivery Sciences Announces Commercialization Agreement with Quintiles to Support the Launch of BUNAVAIL in the U.S.

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has entered into an agreement with Quintiles to provide a range of...

Mar 14, 2014, 06:30 ET

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2013 Annual Report

 BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December...

Mar 05, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences to Present at the 26th Annual ROTH Conference

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will...

Feb 28, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences to Present at the Cowen and Company 34th Annual Health Care Conference

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will...

Feb 13, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences Closes $60 Million Registered Direct Offering

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that it has closed its previously announced registered direct offering with a...

Feb 10, 2014, 07:00 ET
BDSI Logo.  (PRNewsFoto/BioDelivery Sciences International, Inc.)

BioDelivery Sciences to Raise $60 Million in Registered Direct Offering From Institutional Investors

 BioDelivery Sciences International, Inc. (Nasdaq:BDSI) announced that it has entered into a definitive securities purchase agreement with a...